N4 Pharma (N4P), the specialist pharmaceutical company developing Nuvec®, announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary
N4 Pharma (N4P), the specialist pharmaceutical company developing Nuvec®, announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary
Lift Global Ventures (AQSE:LFT), an investment company focused on financial media, technology and the energy sector, announced that its investee company, Public Relations and Investor Relations company, Miriad Limited, has been
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, Avacta, Billington,
Eurasia (EUA), the palladium, platinum, rhodium, iridium and gold mining company, reported its unaudited interim results and operational summary for the six months ended 30 June 2023.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Acuity, Aferian, Avacta,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Artemis, Avacta, Canadian
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Avacta, Belluscura, BSF,
Mortgage Furlough It was a memorable week, mostly for the wrong reasons. Much of it was dominated by the tragedy of Titan, where the fates could not have been more
Chill Brands (CHLL), the consumer packaged-goods distribution company, provided an update on the expansion of its Chill.com product marketplace.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Avacta, AIQ, Abingdon,
Psych Capital (PSY), an investment firm specialising in the healthcare sector, announced that it has agreed to acquire 100% of the issued share capital of Shortwave Pharma Inc., a biopharmaceutical